Loading...

Rebekah White

Title(s)Associate Professor In Residence, Surgery
SchoolHealth Sciences
Phone858-822-4458
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification
    NIH/NCI R21CA198287Sep 1, 2015 - Aug 31, 2017
    Role: Principal Investigator
    RNA Therapeutics for Pancreatic Cancer
    NIH/NCI K08CA142903Aug 17, 2011 - Jul 31, 2015
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Erdem S, White RR. Incidental Gallbladder Cancer: Permission to Operate. Ann Surg Oncol. 2019 Nov 13. PMID: 31722073.
      View in: PubMed
    2. Narayanan JSS, Ray P, Hayashi T, Whisenant TC, Vicente D, Carson DA, Miller AM, Schoenberger SP, White RR. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Cancer Immunol Res. 2019 Oct; 7(10):1714-1726. PMID: 31409607.
      View in: PubMed
    3. Holland MM, Bhutiani N, Kruse EJ, Weiss MJ, Christein JD, White RR, Huang KW, Martin RCG. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. HPB (Oxford). 2019 08; 21(8):1024-1031. PMID: 30737097.
      View in: PubMed
    4. Ray P, White RR. Cell-SELEX Identifies a "Sticky" RNA Aptamer Sequence. J Nucleic Acids. 2017; 2017:4943072. PMID: 28194280.
      View in: PubMed
    5. Mi J, Ray P, Liu J, Kuan CT, Xu J, Hsu D, Sullenger BA, White RR, Clary BM. In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9. Mol Ther Nucleic Acids. 2016 Apr 26; 5:e315. PMID: 27115840.
      View in: PubMed
    6. Speicher PJ, Nussbaum DP, White RR, Zani S, Mosca PJ, Blazer DG, Clary BM, Pappas TN, Tyler DS, Perez A. Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy. Ann Surg Oncol. 2014 Nov; 21(12):4014-9. PMID: 24923222.
      View in: PubMed
    7. White RR, Evans DB. Neoadjuvant chemotherapy for localized pancreatic cancer: too little or too long? Ann Surg Oncol. 2014 May; 21(5):1508-9. PMID: 24452411.
      View in: PubMed
    8. Ray P, Sullenger BA, White RR. Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. Nucleic Acid Ther. 2013 Dec; 23(6):435-42. PMID: 24152208.
      View in: PubMed
    9. Ray P, Cheek MA, Sharaf ML, Li N, Ellington AD, Sullenger BA, Shaw BR, White RR. Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther. 2012 Oct; 22(5):295-305. PMID: 23030589.
      View in: PubMed
    10. Castleberry AW, White RR, De La Fuente SG, Clary BM, Blazer DG, McCann RL, Pappas TN, Tyler DS, Scarborough JE. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol. 2012 Dec; 19(13):4068-77. PMID: 22932857.
      View in: PubMed
    11. Ray P, Rialon-Guevara KL, Veras E, Sullenger BA, White RR. Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. J Clin Invest. 2012 May; 122(5):1734-41. PMID: 22484812.
      View in: PubMed
    12. Ray P, White RR. Aptamers for Targeted Drug Delivery. Pharmaceuticals (Basel). 2010 May 27; 3(6):1761-1778. PMID: 27713328.
      View in: PubMed
    13. Reddy SK, Zorzi D, Lum YW, Barbas AS, Pawlik TM, Ribero D, Abdalla EK, Choti MA, Kemp C, Vauthey JN, Morse MA, White RR, Clary BM. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009 Jul; 16(7):1809-19. PMID: 18979139.
      View in: PubMed
    14. White RR, Kattan MW, Haney JC, Clary BM, Pappas TN, Tyler DS, Brennan MF. Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. Ann Surg Oncol. 2006 Nov; 13(11):1485-92. PMID: 17013688.
      View in: PubMed
    15. Cheng TY, Sheth K, White RR, Ueno T, Hung CF, Clary BM, Pappas TN, Tyler DS. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol. 2006 Jan; 13(1):66-74. PMID: 16372154.
      View in: PubMed
    16. White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS, Jowell PS, Clary BM, Pappas TN, Tyler DS. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005 Mar; 12(3):214-21. PMID: 15827813.
      View in: PubMed